MTDH and hepatocellular carcinoma: Similarly, in HCC exhibiting higher sorafenib resistance, the condition could be partially reversed by the degradation of AEG-1 through interaction with miR-375 in the cancerous cells [127], hence paving way for better sorafenib treatment in HCC patients.